AbCellera Biologics (ABCL) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

AbCellera Biologics (ABCL) overview

AbCellera Biologics (ABCL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 75.1m and operating profit of USD -217m; the year-end share price was 3.42 USD and market capitalisation was USD 1,028m. AbCellera Biologics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AbCellera Biologics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 967mFY 2025
Share price3.42 USDFY 2025 year end
RevenueUSD 75.1mFY 2025
Operating profitUSD -217mFY 2025
Net earningsUSD -146mFY 2025
Market capitalisationUSD 1,028mFY 2025 year end

About AbCellera Biologics

AbCellera discovers and develops antibody-based medicines through a platform combining experimental technology, data science, and drug development capabilities. Its programs span endocrinology, women’s health, immunology, and oncology. The company advances its own therapeutic candidates and collaborates with biotechnology and pharmaceutical partners on drug programs. Its pipeline includes ABCL635 for vasomotor symptoms and other investigational antibodies.

Generate the AbCellera Biologics report

AbCellera Biologics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for AbCellera Biologics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on AbCellera Biologics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.